-
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
15 Dec 2025 21:44 GMT
… the Velcade® development program at Millennium Pharmaceuticals. He also held a number …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Essential Thrombocythemia: Likelihood of Approval
27 Oct 2023 16:35 GMT
… the below form
By GlobalData
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Ixazomib citrate by Millennium Pharmaceuticals for Lymphoblastic Lymphoma: Likelihood of Approval
27 Oct 2023 16:35 GMT
… and graft versus host disease.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Solid Tumor: Likelihood of Approval
10 Feb 2023 09:11 GMT
… is under clinical development by Millennium Pharmaceuticals and currently in Phase I … refractory acute lymphocytic leukemia.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals is a biopharmaceutical company that …
-
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
19 Nov 2025 13:00 GMT
… at Cerulean Pharma, Momenta Pharmaceuticals, Millennium Pharmaceuticals, Biogen, and Boehringer Ingelheim, building …
-
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
06 Nov 2025 23:45 GMT
… Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma …
-
AKTIS ONCOLOGY APPOINTS KYLE KUVALANKA CHIEF FINANCIAL OFFICER
05 Nov 2025 12:36 GMT
… Strategy and Alliance Management at Millennium Pharmaceuticals, the Takeda Oncology Company, and … Vice President, Investor Relations at Millennium Pharmaceuticals. Mr. Kuvalanka holds an MBA …
-
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
31 Oct 2025 02:15 GMT
… neuroblastoma companies including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others …
-
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
28 Oct 2025 12:51 GMT
… in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary …
-
Anaplastic Thyroid Cancer - Pipeline Insight Report 2018 Featuring Exelixis, Eisai, AstraZene, CaIgnyta, Millennium Pharmaceuticals & Novartis - ResearchAndMarkets.com
22 Feb 2018 20:05 GMT
…
Exelixis
Eisai
AstraZene
CaIgnyta Inc.
Millennium Pharmaceuticals Inc.
Novartis
For more information …
About
© 1995-2025